Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.
About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.
The drug, known as Pegylated Interferon alpha-2b and branded as 'PegiHep' by Cadila, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat COVID-19.
The news comes as daily coronavirus infections are surging to new highs in India, which has the world's third-highest caseload after the United States and Brazil. India has so far reported close to 12.5 million infections and more than 164,000 deaths.
Covid-19 Cases Rising Again: WHO Issues Urgent Alert On Potentially Severe Variants Covid-19 Still Driving High Mortality Rate In This Country Biden Returns To White House After Exiting US Presidential Race Parents Gave Names Of Interns, Doctors To CBI In Kolkata Horror: Sources Video: Woman Tries To Jump Off Mumbai's Atal Setu, Saved By Driver, Cops How Extreme Weather Is Leading To Rise In Child Marriages In Pakistan "Shoot Me Up With...": What Matthew Perry Told Assistant Hours Before Death Exotic Trips, Luxury Cars: Inside The Lavish Life Of LA's "Ketamine Queen" Kerala Launches 1st Digital Court For Negotiable Instruments Cases Track Latest News Live on NDTV.com and get news updates from India and around the world.